Asymmetric transfer hydrogenation of α,β-unsaturated, α-tosyloxy and α-substituted ketones
作者:Philip Peach、David J. Cross、Jennifer A. Kenny、Inderjit Mann、Ian Houson、Lynne Campbell、Tim Walsgrove、Martin Wills
DOI:10.1016/j.tet.2005.11.036
日期:2006.2
Asymmetric transferhydrogenation of cyclic and acyclic α,β-unsaturatedketones catalysed by η6-p-cymene/ruthenium(II) and η5-pentamethylcyclopentadienyl/rhodium(III) complexes have been investigated. Cyclicα,β-unsaturatedketones appeared to be more suitable substrates for the synthesis of enantiomerically pure allylic alcohols than do acyclic α,β-unsaturatedketones. A proposed mechanism for the
环状和无环α的不对称转移氢化,β不饱和酮由η催化6 - p -cymene /钌(II)和η 5 -五甲基/铑(III)络合物进行了研究。环状α,β-不饱和酮似乎比无环α,β-不饱和酮更适合用于合成对映体纯的烯丙基醇。讨论了一种由α-甲苯磺酰氧基和卤素取代的苯乙酮形成4-苯基-[1,3]-二氧戊环-2-酮的机理。提出了进一步研究减少α-甲苯磺酰氧基苯乙酮范围和α-取代酮的动态动力学拆分的结果。
[EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
申请人:INTEGRAL BIOSCIENCES PVT LTD
公开号:WO2020012357A1
公开(公告)日:2020-01-16
The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.